Leukemia Inhibitory Factor: A Potential Biomarker and Therapeutic Target in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, treatment-resistant cancer. Five-year survival rate is about 9%, one of the lowest among all solid tumors. Such a poor outcome is partly due to the limited knowledge of tumor biology, and the resulting lack of effective treatment option...

Descripción completa

Detalles Bibliográficos
Autores principales: Wrona, Ewa, Potemski, Piotr, Sclafani, Francesco, Borowiec, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907038/
https://www.ncbi.nlm.nih.gov/pubmed/33630157
http://dx.doi.org/10.1007/s00005-021-00605-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907038/
https://www.ncbi.nlm.nih.gov/pubmed/33630157
http://dx.doi.org/10.1007/s00005-021-00605-w

Ejemplares similares